| Effects of apolipoprotein and low density lipoprotein receptor gene polymorphisms on lipid metabolism, and the lipid risk factors of coronary artery disease | ||
|---|---|---|
| Prev | Next | |
I Savolainen MJ, Korhonen T, Aalto-Setälä K, Kontula K & Kesäniemi YA (1991) Screening for a prevalent LDL receptor mutation in patients with severe hypercholesterolemia. Human Genetics 87: 125-128.
II Korhonen T, Savolainen MJ & Kesäniemi YA. Variation of apolipoprotein B as a possible cause of decreased low density lipoprotein clearance and hypercholesterolemia. Atherosclerosis. In press.
III Korhonen T, Savolainen MJ, Koistinen J, Ikäheimo M, Linnaluoto MK, Kervinen K & Kesäniemi YA (1996) Association of lipoprotein cholesterol and triglycerides with the severity of coronary artery disease in men and women. Atherosclerosis 127: 213-220.
IV Korhonen T, Hannuksela ML, Seppänen S, Kervinen K, Kesäniemi YA & Savolainen MJ. The effect of apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein A I levels in hypercholesterolaemic patients on colestipol and lovastatin treatment. Eur J Clin Invest. In press.
V Korhonen T, Savolainen MJ, Jääskeläinen T & Kesäniemi YA (1995) Effect of a synthetic prostaglandin E2 analogue, RS-86505-007, on plasma lipids and lipoproteins in patients with moderate hypercholesterolemia: efficacy and tolerance of treatment and response in different apolipoprotein polymorphism groups. Eur J Clin Pharmacol 48: 97-102.